臨床検査59巻2号

2015年02月発行

今月の特集1 動脈硬化症の最先端

動脈硬化の診断マーカー

著者： 平山哲¹

所属機関： ¹順天堂大学医学部　臨床検査医学講座

ページ範囲：P.126 - P.131

●脂質の量的および質的な異常は，動脈硬化を促進する．よって，脂質関連検査は，動脈硬化性疾患のスクリーニングや病態評価に有用である．

●炎症マーカーは，特に心血管疾患の予知因子として有用である．

●microRNAは，動脈硬化や各種の癌など，種々の疾患の診断および治療への応用が期待される．

参考文献

1）日本動脈硬化学会（編）：第3〜4章．動脈硬化性疾患予防ガイドライン2012年版．日本動脈硬化学会，p33-43，2012

2）Briel M, Ferreira-Gonzalez I, You JJ, et al：Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis. BMJ　338：b92，2009

3）Stone NJ, Robinson JG, Lichtenstein AH, et al：2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol　63(25 Pt B)：2889-2934，2014

4）Miller WG, Myers GL, Sakurabayashi I, et al：Seven direct methods for measuring HDL and LDL cholesterol compared with ultracentrifugation reference measurement procedures. Clin Chem　56：977-986，2010

5）Miida T, Nishimura K, Okamura T, et al：A multicenter study on the precision and accuracy of homogeneous assays for LDL-cholesterol: comparison with a beta-quantification method using fresh serum obtained from non-diseased and diseased subjects. Atherosclerosis　225：208-215，2012

6）Ariyo AA, Thach C, Tracy R, et al：Lp(a) lipoprotein, vascu

7）Clarke R, Peden JF, Hopewell JC, et al：Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med　361：2518-2528，2009

8）Hirayama S, Soda S, Ito Y, et al：Circadian change of serum concentration of small dense LDL-cholesterol in type 2 diabetic patients. Clin Chim Acta　411：253-257，2010

9）Fukushima Y, Hirayama S, Ueno T, et al：Small dense LDL cholesterol is a robust therapeutic marker of statin treatment in patients with acute coronary syndrome and metabolic syndrome. Clin Chim Acta　412：1423-1427，2011

10）Hoogeveen RC, Gaubatz JW, Sun W, et al：Small dense low-density lipoprotein-cholesterol concentrations predict risk for coronary heart disease: the Atherosclerosis Risk In Communities (ARIC) study. Arterioscler Thromb Vasc Biol　34：1069-1077，2014

11）Shigematsu S, Takahashi N, Hara M, et al：Increased incidence of coronary in-stent restenosis in type 2 diabetic patients is related to elevated serum malondialdehyde-modified low-density lipoprotein. Circ J　71：1697-1702，2007

12）Hayashida K, Kume N, Murase T, et al：Serum soluble lectin-like oxidized low-density lipoprotein receptor-1 levels are elevated in acute coronary syndrome: a novel marker for early diagnosis. Circulation　112：812-818，2005

13）Kume N, Mitsuoka H, Hayashida K, et al：Soluble lectin-like oxidized low-density lipoprotein receptor-1 predicts prognosis after acute coronary syndrome--a pilot study. Circ J　74：1399-1404，2010

14）Inoue N, Okamura T, Kokubo Y, et al：LOX index, a novel predictive biochemical marker for coronary heart disease and stroke. Clin Chem　56：550-558，2010

15）Ross R：Atherosclerosis - an inflammatory disease. N Engl J Med　340：115-126，1999

16）Ridker PM, Danielson E, Fonseca FA, et al：Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med　359：2195-2207，2008

17）Inoue K, Sugiyama A, Reid PC, et al：Establishment of a high sensitivity plasma assay for human pentraxin3 as a marker for unstable angina pectoris. Arterioscler Thromb Vasc Biol　27：161-167，2007

18）前村浩二，志賀太郎：Pentraxin familyの中でのPTX3の位置づけ．生物試料分析　33：313-320，2010

19）Horie T, Baba O, Kuwabara Y, et al：MicroRNA-33 deficiency reduces the progression of atherosclerotic plaque in ApoE-/- mice. J Am Heart Assoc　1：e003376，2012

20）Kuwabara Y, Ono K, Horie T, et al：Increased microRNA-1 and microRNA-133a levels in serum of patients with cardiovascular disease indicate myocardial damage. Circ Cardiovasc Genet　4：446-454，2011